Results from the PHASE2 study NCT04776447 investigating Atezolizumab plus induction chemotherapy and CT-radiotherapy in patients with Stage IIIA-IIIB Non-small Cell Lung Cancer were posted on 2026-07-22. The trial demonstrated that the treatment achieved a 12-month progression-free survival (PFS) rate of 68.4%.
Background
This study investigated Atezolizumab in combination with induction chemotherapy (carboplatin, paclitaxel) and CT-radiotherapy for the treatment of non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer.
Trial design
The PHASE2 study, identified as NCT04776447, enrolled 38 participants with non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer. This open-label, non-randomized, multi-centre clinical trial evaluated the efficacy of Atezolizumab plus induction chemotherapy (carboplatin, paclitaxel) and CT-radiotherapy. The trial assessed progression-free survival (PFS) at 12 months.
Key results
Key efficacy outcomes included:
- The progression-free survival (PFS) at 12 months for the experimental arm was 68.4% of participants.
- Overall Survival (OS) rates were reported as 86.8% of participants and 60.5% of participants.
- Counts of participants related to Overall Response Rate (ORR) were 5 participants, 22 participants, 7 participants, 3 participants, and 1 participant.
What this means
The results from the PHASE2 study NCT04776447 indicate that the combination of Atezolizumab with induction chemotherapy and CT-radiotherapy achieved a notable 12-month progression-free survival rate of 68.4% in patients with non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer. These findings suggest a potential benefit for this multi-modal treatment approach in this challenging patient population.
Source
This information was sourced from ClinicalTrials.gov, documenting the results of trial NCT04776447, which were posted on 2026-07-22. The study details are available on clinicaltrials.gov.